Cardiovascular Implications of Semaglutide in Obesity Management: Redefining Cardiovascular Health Strategies.
Aditya John Binu; Nitin Kapoor
Abstract
Semaglutide is a glucagon-l ike peptide 1 receptor agonist that has been noted to have a significant role in the reduction of body weight and glycaemic control. An increasing body of evidence from recent trials (SUSTAIN-6, SELECT and STEP HF) has shown significant cardiovascular benefits of semaglutide in both patients with and without diabetes and in people who are obese or overweight. Additional studies in a more diverse patient population and safety assessment are warranted prior to adding semaglutide to the increasing pool of guideline-directed medical therapy for the treatment and prevention of cardiac diseases.
Journal | HEART INTERNATIONAL |
ISSN | 2036-2579 |
Published | 01 Jan 2024 |
Volume | 18 |
Issue | 1 |
Pages | 3-4 |
DOI | 10.17925/HI.2024.18.1.1 |
Type | Editorial |
Sponsorship |